Highlights Newsletter 3 This newsletter presents you the following key sessions: Watch the video interview with John Haanen, MD, PhD, about Improved progression-free survival in patients with advanced renal cell carcinoma by combining immunotherapy with tyrosine kinase inhibitors as first-line treatment Neoadjuvant erlotinib delays disease progression in stage IIIA-N2 EGFR-mutated non-small cell lung cancer Durable clinical benefit with nivolumab and low-dose ipilimumab in the first-line treatment of microsatellite instability (MSI)-high metastatic colorectal cancer Improved survival with pembrolizumab in the first-line treatment of metastatic or recurrent head and neck cancer Longer survival with trifluridine/tipiracil in heavily pre-treated patients with metastatic gastric cancer